Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced interim data from the phase IV PRISM II study showing that treatment with NUEDEXTA®...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the safety and efficacy of AVP-825, a Breath-Powered™ Nasal Delivery ...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that COMPASS, its Phase IIIb clinical trial comparing the efficacy and safety of the...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the prevalence and treatment of pseudobulbar affect (PBA), a...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced completion of patient enrollment in the company's phase II, placebo controlled study...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. District Court for the District of Delaware has ruled in favor of Avanir in ...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from its CNS therapeutics franchise, specifically in its pseudobulbar affect...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of data showing that dextromethorphan has antidepressant-like effects in...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the presentation of results from a first-of-its-kind study of pseudobulbar affect (PBA)...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Dr. Mark Corrigan to the company's board of directors. Dr. Corrigan, a ...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) Avanir announced that on February 4, 2014, the Company approved the grant of stock options to new...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2013. (Logo:...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced preliminary financial information (unaudited) for the quarter-ended December 31, 2013, in ...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) Avanir announced that on January 7, 2014, the Company approved the grant of stock options to new...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that PRIME, its phase II clinical trial of the investigational drug AVP-923...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and twelve-months ended September 30, 2013. (Logo:...
vanir Pharmaceuticals, Inc. (NASDAQ: AVNR) Avanir announced that on November 5, 2013, the Company approved the grant of stock options to new...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced preliminary financial information (unaudited) for the year ended September 30, 2013, in...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will host a live webcast in conjunction with its Investor Relations Day on Tuesday, October 29, 2013 at...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient in study AVR-133. The study is a proof of concept,...
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) Avanir announced that on October 1, 2013, the Company approved the grant of stock options to new...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.